Cysteamine-pantetheine disulfide clinical trials
Also written TTI-0102.
How each study uses cysteamine-pantetheine disulfide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cysteamine-pantetheine disulfide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Thiogenesis Therapeutics, Inc. (4) · VA Office of Research and Development (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test cysteamine-pantetheine disulfide.
- Dec 2026Pilot Study of TTI-0102 in CystinosisPhase 2 · Thiogenesis Therapeutics, Inc.
- Jun 2027A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)Phase 2 · Thiogenesis Therapeutics, Inc.
Studies
Open first, then newest update. How each study uses cysteamine-pantetheine disulfide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Pilot Study of TTI-0102 in CystinosisNot yet recruitingPhase 2Thiogenesis Therapeutics, Inc.NCT07837726Written as TTI-0102 (cysteamine-pantetheine disulfide)
- A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)Not yet recruitingPhase 2Thiogenesis Therapeutics, Inc.NCT06990984Written as TTI-0102: cysteamine-pantetheine disulfide
- A Study to Assess TTI-0102 vs Placebo in MELAS PatientsCompletedPhase 2Thiogenesis Therapeutics, Inc.NCT06644534Written as TTI-0102
- Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19WithdrawnPhase 2Thiogenesis Therapeutics, Inc.NCT05212662Written as TTI-0102
- TTI-0102 for Veterans With TBIWithdrawnPhase 1/2VA Office of Research and DevelopmentNCT04262895Written as TTI-0102
Codes
What other systems call cysteamine-pantetheine disulfide · ClinicalTrials.gg INT001819
- MeSH (NLM) C000721994cysteamine-pantetheine disulfideOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000721994 | cysteamine-pantetheine disulfide | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.